This study is testing a new way to treat prostate cancer by combining two types of radiation therapy: Elective Pelvic Ultra Hypofractionated Irradiation Treatment (ePUHRT), which is external radiation, and High Dose Rate Brachytherapy Boost, which is internal radiation where a doctor places a small tube or balloon in the tumor. The goal is to see how well patients tolerate this combined treatment and if it causes side effects. Researchers will measure the percentage of participants who experience acute (short-term) urinary or genital side effects of grade 2 or higher within 3 months. This study is for men aged 18 or older with unfavorable intermediate, high, or very high-risk prostate cancer. The current recruitment status is unclear.

Study design

This interventional study plans to enroll 31 men with prostate cancer. It is not specified if it is randomized or blinded.

What's involved

Participants will receive ePUHRT 5Gy x 5 fractions delivered on noncontiguous weekdays, along with a single HDR boost of 15Gy.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for acute urinary or genital side effects for at least 3 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.